Analysis of opioid-mediated analgesia in Phase III studies of methylnaltrexone for opioid-induced constipation in patients with chronic noncancer pain

Lynn R Webster1
Darren M Brenner2
Andrew C Barrett3
Craig Paterson3
Enoch Bortey3
William P Forbes3

1PRA Health Sciences, Salt Lake City, UT, 2Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, 3Salix, a Division of Valeant Pharmaceuticals North America LLC, Bridgewater, NJ, USA

Background: Subcutaneous methylnaltrexone is efficacious and well tolerated for opioid-induced constipation (OIC) but may theoretically disrupt opioid-mediated analgesia.

Methods: Opioid use, pain intensity, and opioid withdrawal (Objective Opioid Withdrawal Scale [OOWS] and Subjective Opiate Withdrawal Scale [SOWS] scores) were reported in a randomized, double-blind trial with an open-label extension (RCT) and an open-label trial (OLT) evaluating safety in adults with chronic noncancer pain. In the RCT, patients taking ≥50 mg of oral morphine equivalents daily with <3 rescue-free bowel movements weekly received methylnaltrexone 12 mg once daily (n=150), every other day (n=148), or placebo (n=162) for 4 weeks, followed by open-label methylnaltrexone 12 mg (as needed [prn]; n=364) for 8 weeks. In the OLT, patients (n=1,034) on stable opioid doses with OIC received methylnaltrexone 12 mg prn for up to 48 weeks.

Results: Minimal fluctuations of median morphine equivalent dose from baseline (BL) were observed in the RCT double-blind period (BL, 154.8–161.0 mg/d; range, 137.1–168.0 mg/d), RCT open-label period (BL, 156.3–174.6; range, 144.0–180.0) and OLT (BL, 120 mg/d; range, 117.3–121.1 mg/d). No significant change from BL in pain intensity score occurred in any group at weeks 2 or 4 (both P>0.1) of the RCT double-blind period, and scores remained stable during the open-label period and in the OLT (mean change, −0.2 to 0.1). Changes from BL in OOWS and SOWS scores during the double-blind period were not significantly impacted by methylnaltrexone exposure at weeks 2 or 4 (P>0.05 for all).

Conclusion: Methylnaltrexone did not affect opioid-mediated analgesia in patients with chronic noncancer pain and OIC.

Keywords: Relistor, mu-opioid receptor, antagonist, opioids, tolerance, withdrawal

Introduction

It has long been recognized that opioid analgesics are effective for treating moderate-to-severe chronic noncancer pain (CNCP) and are among the most commonly prescribed medications for this indication.1,2 Opioid-induced constipation (OIC) is a common, often problematic adverse effect of opioid therapy and, unlike other adverse effects (eg, nausea), patients rarely develop tolerance to OIC.3,4 The reported prevalence of OIC in patients with CNCP varies based on the definition used and the specific patient population, but has typically been reported to be >40%.1,4–6 A systematic review of eleven studies of opioid therapy (administered from 4 days to 8 weeks) reported that for every three patients treated with opioids, one would be more constipated than a...
patient who received placebo (relative risk, 3.6 [95% confidence interval {CI}, 2.7–4.7]).

OIC can compromise pain management, with gastrointestinal (GI) adverse effects causing patients to skip or reduce their opioid doses, resulting in inadequate pain control.\textsuperscript{4,5} Real-world clinical data also indicate a negative impact of OIC on activities of daily living and work productivity (ie, presenteeism).\textsuperscript{6} Over-the-counter agents (eg, laxatives) are generally unsatisfactory for relieving OIC\textsuperscript{4–6,8} because they do not target the underlying cause – \(\mu\)-opioid receptor activation in the GI tract.\textsuperscript{9,10}

Methylnaltrexone, a derivative of naltrexone, is a selective, peripherally acting \(\mu\)-opioid receptor antagonist that inhibits opioid-induced increases in orocecal transit time and gastric emptying.\textsuperscript{11–13} The efficacy and safety of methylnaltrexone for the treatment of OIC have been demonstrated in patients with advanced illness receiving palliative care.\textsuperscript{14–19} Additionally, in a randomized, controlled study in patients with chronic noncancer-related pain of\textsuperscript{13} (ie, presenteeism).\textsuperscript{6} Over-the-counter agents (eg, laxatives) are generally unsatisfactory for relieving OIC\textsuperscript{4–6,8} because they do not target the underlying cause – \(\mu\)-opioid receptor activation in the GI tract.\textsuperscript{9,10}

Methylnaltrexone at therapeutic doses does not appear to interfere with the central analgesic effects of opioid pain medications,\textsuperscript{20} and it has not been known to precipitate withdrawal when concomitantly administered with opioids.\textsuperscript{14–17} However, based on data from studies in animals, it is theoretically possible that analgesia could be affected by feedback to the central nervous system from peripheral neurons.\textsuperscript{21} Indeed, preliminary indirect data suggest a potential influence of supertherapeutic doses of methylnaltrexone (\(\geq 45 \text{ mg/kg}\)) on psychopharmacologic actions of morphine.\textsuperscript{22}

The objective of this study was to examine the potential effects of methylnaltrexone (in a dose of 12 mg) on opioid medication use, opioid analgesia, and opioid withdrawal symptoms in patients with CNCP and OIC, who participated in a Phase III, randomized, placebo-controlled trial (RCT)\textsuperscript{13} and a Phase III, open-label trial (OLT) of methylnaltrexone.

**Methods**

**Patient population**

Randomized, placebo-controlled trial

The patient population and the study design of the RCT have been previously published.\textsuperscript{13} Briefly, adults who had a history of chronic noncancer-related pain of \(\geq 2\) months, who also had received oral, transdermal, or subcutaneous opioids (average daily dose of \(\geq 50\) mg oral morphine equivalents for \(\geq 2\) weeks) for at least 1 month’s duration, were screened. Patients were eligible for study inclusion if they had \(<3\) RFBMs per week and \(\geq 1\) of the following: hard or lumpy stools, straining during bowel movements (BMs), or sensation of incomplete evacuation. An RFBM was defined as any BM occurring without laxative use within the previous 24 hours. Patients with inflammatory bowel disease, evidence of bowel obstruction or impaction, and those with a history of rectal bleeding, malignancy (within the previous 5 years), or chronic constipation occurring before beginning opioid therapy were excluded. Patients who had received subcutaneous methylnaltrexone in the past, those who were breast-feeding or pregnant, and those who had a history of drug or alcohol abuse (within the previous year) were also ineligible for participation.

**Open-label trial**

Key patient inclusion and exclusion criteria were similar to those of the RCT.\textsuperscript{13} Ambulatory patients \(\geq 18\) years of age who had experienced pain unrelated to a malignant condition for \(>2\) months, who were receiving daily oral, transdermal, intravenous, or subcutaneous opioids, and who had OIC \(\geq 1\) month prior were screened. OIC was defined as having \(\geq 2\) of the following: hard or lumpy stools for \(\geq 25\%\) of BMs; straining during \(\geq 25\%\) of BMs; a sensation of incomplete evacuation after \(\geq 25\%\) of BMs; facilitation of a BM by manual maneuvers \(\geq 25\%\) of the time; or \(<3\) RFBMs per week. Patients who were pregnant or breast-feeding and those who had a diagnosis of clinically significant GI disorder (eg, bowel obstruction, fecal incontinence, rectal prolapse) were not allowed to participate. Patients were also ineligible if they had a history of drug or alcohol abuse during the previous year or had a history of inflammatory bowel disease, irritable bowel syndrome, megacolon, rectal bleeding, malignancy, or chronic constipation occurring before the onset of opioid therapy.

**Study design**

Both trials were conducted in accordance with the International Conference on Harmonisation Guideline for Good Clinical Practice and the ethical principles according to the Declaration of Helsinki. All patients provided written informed consent.

Randomized, placebo-controlled trial

The randomized, double-blind, multicenter, Phase III trial was conducted at 91 sites in the USA and Canada between August 2007 and November 2008 (ClinicalTrials.gov
Withdrawal symptom typically included in the total scores of the OOWS and SOWS and may be associated with constipation, is also common with administration of methylnaltrexone, it was considered a potentially confounding factor. Therefore, OOWS and SOWS scores in the RCT and in the OLT were calculated both with and without items related to abdominal cramping.

In the OLT, OOWS and SOWS scores were determined at BL before administration of methylnaltrexone, 1 hour after drug administration, and during the double-blind period at weeks 2 and 4. The SOWS score was also determined during weeks 6, 8, and 12 of the open-label period. In the OLT, OOWS and SOWS were performed on day 1 before administration of treatment and approximately 1 hour after administration.

Statistical analyses
In the double-blind period of the RCT, analyses involved the modified intention-to-treat population, which included all patients who were randomly assigned to treatment (ie, the intent-to-treat population) and received ≥1 dose of study drug. During the open-label period of the RCT, analyses included all patients who received ≥1 dose of study drug. Analyses were conducted using observed data (ie, no imputation). An analysis of covariance model with treatment as a factor and BL as covariate was used to compare morphine dose equivalent, pain intensity, and OOWS and SOWS between-treatment groups in the double-blind period. All variables ascertained during the open-label period were reported as descriptive statistics. Analyses of the change from BL pain intensity score during the open-label period were conducted using a paired t-test. Sample size for this study was based on primary and secondary endpoints and has been previously reported. Briefly, to achieve a statistical power of 95% to detect a treatment effect of 15% in the number of patients who had an RFBM within 4 hours after the first dose of study medication, using a two-sided chi-square test with a significance level of 0.05, it was determined that 314 and 157 patients were required in the methylnaltrexone and placebo groups, respectively.
In the OLT, analyses included all patients who received ≥1 dose of methylnaltrexone, and the analyses were performed on observed data. A formal power calculation was not performed for the OLT; however, it was anticipated that at least 1,000 patients would be required to obtain 300 patients for 6-month exposure and 100 patients for the 1-year exposure groups.

Results

Patient disposition and demographics

In the RCT, 469 of the 1,037 (45.2%) patients screened were included in the study and randomly assigned to treatment with methylnaltrexone 12 mg qd, methylnaltrexone 12 mg qod, or placebo for 4 weeks (Figure 1A).13 Of these, 460 patients received ≥1 dose of study medication; most (n=388; 84.3%)...
of the 460 patients completed the double-blind phase. The majority of patients (95.9%) who completed the double-blind phase were then enrolled in the open-label phase, but only 364 patients (93.8%) received ≥1 dose of study medication in the open-label phase, and of these, 303 (83.2%) completed the trial (Figure 1A). The most common reason for discontinuation in the RCT and open-label phase was adverse events (AEs), of which abdominal pain was the most common, causing discontinuations in 2.0% and 3.4% of patients who received methylnaltrexone qd and qod, respectively, and in 1.1% of patients in the open-label phase. In the OLT, 1,034 of 1,673 (61.8%) patients screened were enrolled and received ≥1 dose of methylnaltrexone (Figure 1B). Of those, 477 patients (46.1%) completed the study; experiencing an AE was the most common reason for study discontinuation. The most common AEs causing discontinuation were abdominal pain (4.7%), nausea (2.5%), and diarrhea (2.3%).

Demographics and BL characteristics were similar across the three treatment groups in the RCT and between the RCT and OLT studies (Table 1). However, the total median BL MED across the three treatment groups (n=460) in the double-blind phase of the RCT was higher (160.0 mg/d) compared with the OLT (120.0 mg/d). In both phases of the RCT and in the OLT, most patients were white and female, with back pain reported as the primary pain condition (Table 1). The most commonly prescribed opioids during the RCT double-blind period across the three treatment groups (n=460) were oxycodone (n=93, 20.2%), methadone (n=86, 18.7%), and hydrocodone (n=66, 14.3%); these medications were also the opioids most commonly used by patients (n=364) during the open-label phase (oxycodone: n=85, 23.4%; methadone: n=71, 19.5%; hydrocodone: n=58, 15.9%). In the double-blind period of the RCT, use of hydrocodone (range, 12.7%–15.5%) and oxycodone (range, 18.2%–23.3%) was similar among the treatment groups. Methadone use was greater in the methylnaltrexone 12 mg qd (20.7%) and placebo (22.2%) groups versus the methylnaltrexone 12 mg qod group (12.8%). The most commonly prescribed opioids during the OLT (n=1,034) were morphine sulfate (n=232, 22.4%), oxycodone (n=214, 20.7%), and methadone (n=153, 14.8%).

### Median daily morphine equivalent dose

In the RCT, the median daily MED (assessed weekly) showed minimal fluctuations during both the double-blind and open-label periods (Figure 2A); however, a significant increase from BL in median daily MED was observed with methylnaltrexone

---

### Table 1 Demographics and baseline characteristics

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>RCT</th>
<th>OLT</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Double-blind phase</td>
<td>Open-label phase</td>
</tr>
<tr>
<td></td>
<td>Methylnaltrexone qd (n=150)</td>
<td>Methylnaltrexone qd (n=148)</td>
</tr>
<tr>
<td>Mean age, yr (range)</td>
<td>48.0 (24 to 78)</td>
<td>50.0 (24 to 80)</td>
</tr>
<tr>
<td>Female, n (%)</td>
<td>93 (62.0)</td>
<td>99 (66.1)</td>
</tr>
<tr>
<td>Race, n (%)</td>
<td>White</td>
<td>Black</td>
</tr>
<tr>
<td></td>
<td>139 (92.7)</td>
<td>7 (4.7)</td>
</tr>
<tr>
<td></td>
<td>Black</td>
<td>133 (89.9)</td>
</tr>
<tr>
<td></td>
<td>Other</td>
<td>4 (2.7)</td>
</tr>
<tr>
<td>Primary pain condition, n (%)</td>
<td>Back pain</td>
<td>96 (64.0)</td>
</tr>
<tr>
<td></td>
<td>Cervical/neck pain</td>
<td>6 (4.0)</td>
</tr>
<tr>
<td></td>
<td>Fibromyalgia syndrome</td>
<td>13 (8.7)</td>
</tr>
<tr>
<td></td>
<td>Neuropathic pain</td>
<td>4 (2.7)</td>
</tr>
<tr>
<td></td>
<td>Osteoarthritis</td>
<td>12 (8.0)</td>
</tr>
<tr>
<td></td>
<td>Rheumatoid arthritis</td>
<td>2 (1.3)</td>
</tr>
<tr>
<td></td>
<td>Complex regional pain syndrome</td>
<td>3 (2.0)</td>
</tr>
<tr>
<td></td>
<td>Lower extremity/hip pain</td>
<td>4 (2.7)</td>
</tr>
<tr>
<td></td>
<td>Migraines/headaches</td>
<td>2 (1.3)</td>
</tr>
<tr>
<td></td>
<td>Pelvic pain</td>
<td>1 (0.7)</td>
</tr>
<tr>
<td></td>
<td>Trigeminal neuralgia</td>
<td>1 (0.7)</td>
</tr>
<tr>
<td></td>
<td>Upper extremity/shoulder pain</td>
<td>2 (1.3)</td>
</tr>
<tr>
<td></td>
<td>Other</td>
<td>4 (2.7)</td>
</tr>
<tr>
<td>Mean morphine equivalent dose, mg/d (range)</td>
<td>161.0 (45.5 to 831.2)</td>
<td>158.4 (7.2 to 1,334.3)</td>
</tr>
<tr>
<td>Mean pain intensity score (SD)</td>
<td>6.2 (1.9)</td>
<td>6.3 (1.9)</td>
</tr>
</tbody>
</table>

**Note:** Adapted from Michna E, Blonsky ER, Schulman S, et al. Subcutaneous methylnaltrexone for treatment of opioid-induced constipation in patients with chronic, nonmalignant pain: a randomized controlled study. J Pain. 2011;12(5):554–562. Copyright © 2011, with permission from Elsevier. Additional study data was also used.

**Abbreviations:** d, day; OLT, open-label trial; prn, as needed; qd, once daily; qod, every other day; RCT, randomized controlled trial; SD, standard deviation; yr, years.
12 mg qod during week 1 of the double-blind period versus placebo ($P<0.02$). In the open-label period, median daily MED remained constant (methylnaltrexone 12 mg qd: range, 150.0–180.0 mg/d; methylnaltrexone qod: range, 144.0–162.6 mg/d; placebo: range, 160.0–180.0 mg/d) and was not impacted by treatment assignment during the double-blind phase. In the OLT, median daily MED (assessed monthly) also remained unchanged from BL, ranging from 117.3 to 121.1 mg/d (Figure 2B).

**Pain intensity**

In the RCT, mean pain intensity scores for methylnaltrexone qd and qod exhibited no significant changes from BL at weeks 2 and 4 of the double-blind period compared with placebo (Table 2). Mean pain intensity scores also remained stable with methylnaltrexone 12 mg during the open-label period (mean change from BL at week 12, −0.2; $P=0.1$ versus BL). In addition, there were no differences in pain intensity scores during the open-label treatment when evaluated by prior treatment during the RCT. Consistent with results observed during the RCT, mean pain intensity scores were unchanged from BL up to 48 weeks of treatment in the OLT (Table 3).

**Opioid withdrawal symptoms**

During the RCT double-blind phase, minimal changes in OOWS scores were observed (Table 4). Similar trends in
Table 2 Change from baseline in pain intensity during RCT double-blind phase

<table>
<thead>
<tr>
<th>Treatment (n)</th>
<th>Mean score (SD)</th>
<th>Change from baseline (SD)</th>
<th>Change versus placebo&lt;sup&gt;a&lt;/sup&gt;</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Week 2</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Methylaltrexone 12 mg qd (n=132)</td>
<td>6.2 (1.9)</td>
<td>0.0 (1.7)</td>
<td>0.1</td>
<td>0.69</td>
</tr>
<tr>
<td>Methylaltrexone 12 mg qod (n=132)</td>
<td>6.1 (1.9)</td>
<td>−0.1 (1.5)</td>
<td>0.0</td>
<td>0.97</td>
</tr>
<tr>
<td>Placebo (n=133)</td>
<td>6.2 (2.0)</td>
<td>−0.1 (1.4)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Week 4</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Methylaltrexone 12 mg qd (n=122)</td>
<td>6.1 (1.9)</td>
<td>−0.2 (1.6)</td>
<td>−0.1</td>
<td>0.64</td>
</tr>
<tr>
<td>Methylaltrexone 12 mg qod (n=120)</td>
<td>5.9 (1.7)</td>
<td>−0.3 (1.5)</td>
<td>−0.3</td>
<td>0.15</td>
</tr>
<tr>
<td>Placebo (n=143)</td>
<td>6.3 (2.0)</td>
<td>−0.1 (1.8)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Note: *Difference in adjusted change from baseline versus placebo.

Abbreviations: qd, once daily; qod, every other day; RCT, randomized controlled trial; SD, standard deviation.

OOWS scores were observed when scores were calculated with and without abdominal-cramping-related items. At BL (day 1), when the OOWS score was determined prior to and 1 hour after initial drug exposure, patients who received methylaltrexone 12 mg qod had slightly greater withdrawal symptoms 1 hour after drug exposure compared with placebo (mean score difference [95% CI], 0.4 [0.2–0.6] and 0.3 [0.1–0.5] with and without abdominal-cramping-related items, respectively; P<0.001 for both). No other statistically significant differences in OOWS score were observed in other treatment groups or throughout the RCT.

Changes from BL in SOWS scores were small and tended to slightly fluctuate throughout the RCT double-blind period (Table 5). As observed with OOWS, overall trends were similar with SOWS scores calculated with and without abdominal-cramping-related items. At BL, 1 hour after first drug treatment, a significant difference in SOWS score versus placebo was observed in patients who received methylaltrexone 12 mg qod (difference [95% CI]: 2.1 [0.6–3.7], P<0.01 and 1.7 [0.2–3.1], P<0.03, with and without abdominal-cramping-related items, respectively); such differences versus placebo were not observed at any other time during the RCT double-blind period for methylaltrexone 12 mg qod.

Table 3 Change from baseline in pain intensity during OLT

<table>
<thead>
<tr>
<th>Assessment time point</th>
<th>Patients, n&lt;sup&gt;b&lt;/sup&gt;</th>
<th>Mean score (SD)</th>
<th>Mean change from baseline (SD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Week 4</td>
<td>898</td>
<td>6.0 (2.0)</td>
<td>−0.1 (1.8)</td>
</tr>
<tr>
<td>Week 8</td>
<td>789</td>
<td>6.0 (2.1)</td>
<td>0.0 (2.0)</td>
</tr>
<tr>
<td>Week 12</td>
<td>733</td>
<td>6.1 (2.1)</td>
<td>0.1 (1.9)</td>
</tr>
<tr>
<td>Week 16</td>
<td>689</td>
<td>6.1 (2.2)</td>
<td>0.0 (2.0)</td>
</tr>
<tr>
<td>Week 24</td>
<td>626</td>
<td>6.1 (2.2)</td>
<td>0.0 (2.0)</td>
</tr>
<tr>
<td>Week 32</td>
<td>582</td>
<td>6.1 (2.1)</td>
<td>0.0 (2.0)</td>
</tr>
<tr>
<td>Week 40</td>
<td>521</td>
<td>6.1 (2.1)</td>
<td>0.0 (2.0)</td>
</tr>
<tr>
<td>Week 48</td>
<td>435</td>
<td>6.1 (2.1)</td>
<td>0.0 (2.1)</td>
</tr>
<tr>
<td>Follow-up visit</td>
<td>286</td>
<td>6.2 (2.2)</td>
<td>0.1 (2.0)</td>
</tr>
</tbody>
</table>

Note: *Data available for 1,029 patients at baseline.

Abbreviations: OLT, open-label trial; SD, standard deviation.

During the OLT, the mean change from BL in OOWS score (mean difference [standard deviation [SD]], 0.2 [1.1] and 0.1 [0.9], with and without abdominal-cramping-related items, respectively) and SOWS score (mean difference [SD], −2.5 [7.1] and −2.8 [6.6], respectively) was small.

Discussion

The stability of median daily MED and pain intensity scores and the lack of any clinically meaningful central opioid withdrawal effects with methylaltrexone in both RCT and OLT indicate that methylaltrexone treatment for OIC in patients with CNCP does not reduce opioid-mediated analgesia or precipitate opioid withdrawal. These results are consistent with previous reports that demonstrated a lack of effect on analgesia and central withdrawal with intravenous<sup>13</sup> and subcutaneous<sup>14–17,25</sup> methylaltrexone in patients receiving opioids.

Opioid withdrawal syndrome is a multifaceted symptom complex including central (altered heart rate, anxiety, or irritability) and peripheral (bone or joint aches, GI upset) withdrawal symptoms. Methylaltrexone antagonizes µ-opioid receptors in the GI tract (periphery), but has limited effects on central opioid receptors because of its polarity and lipid solubility, which restricts its ability to cross the blood–brain barrier. In the current study, opioid dosage required for pain relief, pain intensity scores, and objective and subjective measures of pain were generally unaffected by methylaltrexone, supporting its lack of centrally mediated effects. A single significant between-group difference in OOWS and SOWS scores was reported at week 1 in the methylaltrexone qod group versus placebo, but, because no difference was observed in the methylaltrexone qd group (ie, patients who had a higher cumulative methylaltrexone exposure) and the difference was not apparent after week 1, this was likely an artifact. Observable effects on central manifestations of withdrawal (eg, anxiety) were minimal in the RCT<sup>13</sup> and OLT<sup>26</sup> but other effects linked to opioid withdrawal (abdominal pain) were reported. However, abdominal...
### Table 4 Change from baseline in OOWS, with and without abdominal-cramping-related items during the RCT double-blind phase

<table>
<thead>
<tr>
<th>Treatment (n)</th>
<th>OOWS scorea Without abdominal-cramping-related items</th>
<th></th>
<th>OOWS scorea With abdominal-cramping-related items</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mean score (SD) Change from baseline (SD) Change versus baseline (SD)</td>
<td></td>
<td>Mean score (SD) Change from baseline (SD) Change versus baseline (SD)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Day 1</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Methylaltrexone 12 mg qd (n=148)</td>
<td>0.4 (1.1) 0.1 (0.6) 0.1 (–0.1 to 0.3) 0.3</td>
<td></td>
<td>0.5 (1.2) 0.2 (0.7) 0.1 (–0.1 to 0.4) 0.2</td>
<td></td>
</tr>
<tr>
<td>Methylaltrexone 12 mg qod (n=145)</td>
<td>0.6 (1.6) 0.3 (1.3) 0.3 (0.1 to 0.5) &lt;0.001</td>
<td></td>
<td>0.7 (1.8) 0.4 (1.5) 0.4 (0.2 to 0.6) &lt;0.001</td>
<td></td>
</tr>
<tr>
<td>Placebo (n=161)</td>
<td>0.2 (0.8) 0.0 (0.4)</td>
<td></td>
<td>0.2 (0.9) 0.0 (0.5)</td>
<td></td>
</tr>
<tr>
<td>Week 2</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Methylaltrexone 12 mg qd (n=135)</td>
<td>0.4 (1.1) 0.1 (0.4) 0.1 (–0.1 to 0.2) 0.3</td>
<td></td>
<td>0.4 (1.2) 0.1 (0.5) 0.1 (–0.1 to 0.2) 0.3</td>
<td></td>
</tr>
<tr>
<td>Methylaltrexone 12 mg qod (n=132)</td>
<td>0.3 (1.0) 0.0 (0.6) 0.0 (–0.1 to 0.1) 0.8</td>
<td></td>
<td>0.3 (1.0) 0.0 (0.7) 0.0 (–0.1 to 0.1) 0.9</td>
<td></td>
</tr>
<tr>
<td>Placebo (n=152)</td>
<td>0.2 (0.7) 0.0 (0.6)</td>
<td></td>
<td>0.2 (0.7) 0.0 (0.6)</td>
<td></td>
</tr>
<tr>
<td>Week 4</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Methylaltrexone 12 mg qd (n=124)</td>
<td>0.3 (1.1) 0.0 (0.7) 0.0 (–0.1 to 0.2) 0.5</td>
<td></td>
<td>0.3 (1.1) 0.0 (0.7) 0.1 (–0.1 to 0.2) 0.4</td>
<td></td>
</tr>
<tr>
<td>Methylaltrexone 12 mg qod (n=120)</td>
<td>0.3 (1.1) 0.0 (0.6) 0.1 (–0.1 to 0.2) 0.5</td>
<td></td>
<td>0.3 (1.1) 0.0 (0.6) 0.1 (–0.1 to 0.2) 0.4</td>
<td></td>
</tr>
<tr>
<td>Placebo (n=143)</td>
<td>0.2 (0.6) 0.0 (0.6)</td>
<td></td>
<td>0.2 (0.6) 0.0 (0.6)</td>
<td></td>
</tr>
</tbody>
</table>

**Notes:** The OOWS consists of 13 items; each item that is considered to be present according to the observer receives 1 point. Higher scores indicate more severe withdrawal (maximum score, 13), without abdominal-cramping-related items (maximum score, 12); *difference in adjusted change from baseline versus placebo; approximately 1 hour after drug administration.

**Abbreviations:** CI, confidence interval; OOWS, objective opioid withdrawal scale; qd, once daily; qod, every other day; RCT, randomized controlled trial; SD, standard deviation.

### Table 5 Change from baseline in SOWS during RCT double-blind phase

<table>
<thead>
<tr>
<th>Treatment (n)</th>
<th>SOWS Score Without abdominal-cramping-related items</th>
<th></th>
<th>SOWS Score With abdominal-cramping-related items</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mean score (SD) Change from baseline (SD) Change versus baseline (SD)</td>
<td></td>
<td>Mean score (SD) Change from baseline (SD) Change versus baseline (SD)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Day 1</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Methylaltrexone 12 mg qd (n=143)</td>
<td>11.5 (10.7) –2.2 (7.1) 1.2 (–0.2 to 2.7) 0.09</td>
<td></td>
<td>12.7 (11.4) –2.1 (7.6) 1.7 (0.1 to 3.2) 0.04</td>
<td></td>
</tr>
<tr>
<td>Methylaltrexone 12 mg qod (n=137)</td>
<td>11.8 (11.9) –1.7 (7.4) 1.7 (0.2 to 3.1) 0.03</td>
<td></td>
<td>12.9 (12.7) –1.5 (8.0) 2.1 (0.6 to 3.7) 0.01</td>
<td></td>
</tr>
<tr>
<td>Placebo (n=154)</td>
<td>9.9 (9.5) –3.3 (5.9)</td>
<td></td>
<td>10.5 (10.1) –3.6 (6.2)</td>
<td></td>
</tr>
<tr>
<td>Week 2</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Methylaltrexone 12 mg qd (n=130)</td>
<td>12.7 (9.6) –0.7 (8.5) –0.6 (–2.3 to 1.1) 0.52</td>
<td></td>
<td>13.8 (10.2) –0.7 (9.0) –0.5 (–2.3 to 1.3) 0.61</td>
<td></td>
</tr>
<tr>
<td>Methylaltrexone 12 mg qod (n=130)</td>
<td>12.5 (9.8) –0.6 (8.7) –0.6 (–2.3 to 1.1) 0.49</td>
<td></td>
<td>13.6 (10.3) –0.4 (9.2) –0.3 (–2.1 to 1.5) 0.71</td>
<td></td>
</tr>
<tr>
<td>Placebo (n=151)</td>
<td>13.2 (10.9) –0.1 (7.2)</td>
<td></td>
<td>14.0 (11.6) –0.1 (7.8)</td>
<td></td>
</tr>
<tr>
<td>Week 4</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Methylaltrexone 12 mg qd (n=121)</td>
<td>11.4 (9.9) –2.0 (8.4) –1.9 (–3.8 to 0.0) 0.05</td>
<td></td>
<td>12.2 (10.5) –2.1 (9.0) –2.0 (–3.9 to 0.0) 0.06</td>
<td></td>
</tr>
<tr>
<td>Methylaltrexone 12 mg qod (n=117)</td>
<td>12.2 (10.2) –0.5 (9.8) –0.6 (–2.5 to 1.3) 0.52</td>
<td></td>
<td>13.3 (10.8) –0.3 (10.5) –0.4 (–2.4 to 1.7) 0.72</td>
<td></td>
</tr>
<tr>
<td>Placebo (n=142)</td>
<td>13.4 (10.7) –0.2 (7.4)</td>
<td></td>
<td>14.2 (11.2) –0.2 (7.9)</td>
<td></td>
</tr>
</tbody>
</table>

**Notes:** The SOWS is a 16-item, patient-reported scoring system. Each item is scored from 0 (not at all) to 4 (extremely), with a total maximum score of 64; without abdominal-cramping-related items (maximum score, 60); *difference in adjusted change from baseline versus placebo; approximately 1 hour after drug administration.

**Abbreviations:** CI, confidence interval; qd, once daily; qod, every other day; RCT, randomized controlled trial; SD, standard deviation; SOWS, subjective opiate withdrawal scale.
pain may be related to the normal, propulsive effects of a
BM; therefore, it is a potential confounder when attempting
to ascertain whether such GI AEs might be related to opioid
withdrawal or merely to methylnaltrexone’s activity of BM
induction. Interestingly, a post hoc analysis of two ran-
domized, placebo-controlled studies of OIC in patients with
advanced illness showed that the incidence of abdominal
pain decreased after the first dose of methylnaltrexone, while
response to methylnaltrexone treatment was maintained.
The similarity between OOWS and SOWS scores calculated
with and without abdominal-cramping-related items in the
current study suggests that abdominal symptoms that may be
associated with methylnaltrexone did not significantly alter
overall patient pain perception.

The RCT double-blind period was of relatively short
duration (ie, 6 weeks), thereby limiting conclusions regarding
long-term effects of methylnaltrexone on opioid analgesia
compared with placebo; however, the similarity of the results
from the RCT double-blind (ie, 4-week duration) and open-
label (8-week duration) periods and those from the OLT
(48-week duration) supports the conclusion that analgesia
would not be affected with long-term methylnaltrexone use.
The current study also did not assess OOWS and SOWS
throughout the OLT. Again, this limits the long-term con-
clusions that may be drawn from the study. However, the
impact of methylnaltrexone administration on OOWS and
SOWS scores would be anticipated to be observable within
the short, postinjection time frame in which the OOWS
and SOWS were administered in the OLT. The lack of any
alterations in OOWS and SOWS supports the longer term
data reported in the RCT.

Conclusion

Results indicated no demonstrable effects of the peripher-
ally acting µ-opioid receptor antagonist methylnaltrexone on
opioid-mediated analgesia. Thus, methylnaltrexone may be
considered as an option for the treatment of OIC, without
significant concerns of compromising pain management
strategies in patients with CNCP.

Acknowledgments

Technical editorial and medical writing assistance, under the
direction of the authors, was provided by Mary Beth Moncrief,
PhD, and Jillian R Gee, PhD, Synchrony Medical Communica-
tions, LLC, West Chester, PA, USA. Funding for this support
was provided by Salix, a Division of Valeant Pharmaceuticals
North America LLC, Bridgewater, NJ, USA.

The trial was funded by Wyeth Research, which was
acquired by Pfizer Inc. in October 2009. The current analyses
were supported by Salix.

Author Contributions

All authors contributed toward data analysis, drafting and
critically revising the paper. The authors all had complete
access to the data and approved the final draft of the manu-
script. They agree to be accountable for all aspects of the
work.

Disclosure

Lynn R Webster has received financial support from
BioDelivery Sciences International, Raleigh, NC, USA; Cara
Therapeutics, Shelton, CT, USA; Charleston Labs, Jupiter,
FL, USA; Collegium Pharmaceutical, Canton, MA, USA;
Egalet Corporation, Wayne, PA, USA; Grünenthal USA,
Bedminster Township, NJ, USA; Inspirion, Basking Ridge,
NJ, USA; Insys Therapeutics, Chandler, AZ, USA; Jazz Phar-
maceuticals, Palo Alto, CA, USA; Kaléo Pharmaceuticals,
Richmond, VA, USA; Mallinckrodt Pharmaceuticals, St.
Louis, MO, USA; Nektar Therapeutics, San Francisco, CA,
USA; Orexo, Morristown, NJ, USA; Pfizer, New York, NY,
USA; Signature Therapeutics, Palo Alto, CA, USA; Teva,
Malvern, PA, USA; Trevena, Exton, PA, USA; and Zogenix,
San Diego, CA, USA.

Darren M Brenner is a consultant and/or speaker for Salix,
a Division of Valeant Pharmaceuticals North America LLC,
Bridgewater, NJ, USA; Forest Laboratories (acquired by
Actavis), New York, NY, USA; Ironwood Pharmaceuticals,
Cambridge, MA, USA; Procter & Gamble, Cincinnati, OH,
USA; AstraZeneca, Wilmington, DE, USA; and the Gi Health
Foundation Clark, NJ, USA.

Andrew C Barrett, Craig Paterson, Enoch Bortey, and
William P Forbes are former employees of Salix. The authors
report no other conflicts of interest in this work.

References

1. Kalso E, Edwards JE, Moore RA, McQuay HJ. Opioids in chronic non-
372–380.
2. Bader S, Jaroslawski K, Blum HE, Becker G. Opioid-induced constipation
in advanced illness: safety and efficacy of methylnaltrexone bromide. Clin
Med Insights Oncol. 2011;5:201–211.
3. Clemens KE, Klaschik E. Managing opioid-induced constipation in
advanced illness: focus on methylnaltrexone bromide. Ther Clin Risk
The prevalence, severity, and impact of opioid-induced bowel dysfunction: results of a US and European patient survey (PROBE 1).


